Pharma Business - February 6, 2015
AZ Plan Clears First Hurdle
AstraZeneca announced that Cambridge City Council has granted planning permission for the company’s new global research and development center and corporate headquarters in the city. The facility will be located on the Cambridge Biomedical Campus and will be home to approximately 2,000 employees. “We are very pleased with…[the] decision by Cambridge City Council. Work is […]
Acquisition - February 5, 2015
AstraZeneca Teams with Box
AstraZeneca is making Box’s cloud content sharing and collaboration platform available to its 51,000 employees across more than 100 countries. The platform will provide secure collaboration company-wide and with external parties, as well as enable mobile access to information. “AstraZeneca’s move to Box follows our deep emphasis on life sciences, which is an important sector […]
Drug Development Pharma - January 28, 2015
FDA Approves Generic Nexium
AstraZeneca’s extended protection period for the $3 billion-selling heartburn drug Nexium has come to an end, now that the U.S. Food and Drug Administration (FDA) has approved the first generic version of Nexium. Ivax Pharmaceuticals, Inc., a subsidiary of Teva Pharmaceuticals USA, has won approval to market the medication in 20 and 40 milligram capsules. […]
Pharma Business - January 27, 2015
Group Protests AZ Lab Plans
An online petition opposing AstraZeneca PLC’s plans to build an animal testing lab as part of a proposed research center has collected almost 5,000 signatures in fewer than two weeks. The animal rights activist organization Cambridge against AstraZeneca PLC Planning, or CAP, is opposed to the proposed animal testing facilities at the planned site. The […]
Drug Development Pharma - January 26, 2015
EMA Accepts AZ Gout Drug
AstraZeneca’s application for lesinurad, an unevenly successful gout treatment, has been accepted by the European Medicines Agency (EMA). AstraZeneca acquired lesinurad as part of the $1.3 billion purchase of Ardea Biosciences in 2013. The EMA’s Committee for Medicinal Products for Human Use now will decide whether to grant approval to lesinurad to supplement the usual […]
Clinical Trials - January 22, 2015
Astra’s Brilinta Gets a Boost
On the heels of positive outcomes from a second study of the blood thinner Brilinta, AstraZeneca plans to use the results to bolster an application to the U.S. Food and Drug Administration (FDA) to expand and extend the use of the anti-platelet drug. Called the Pegasus study, it followed 21,000 patients who’d had heart attacks and found that long-term use of Brilinta in […]
